Lex points out an interesting aspect of the Roche-Genentech deal:
If the middleman won’t lend to you except at usurious rates of interest, just cut him out. That’s what Roche did. The Swiss drugmaker has raised $39bn of the $47bn it needs to fund its recently agreed acquisition of Genentech, the US biotechnology group, by tapping directly into the bond market. There was no bank finance to be seen. Read more



